2021 Fiscal Year Final Research Report

Regeneration of bladder smooth muscle by in vivo direct reprogramming

Research Project

PDF

Project/Area Number	19K09719
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Review Section	Basic Section 56030:Urology-related
Research Institution	Kyoto Prefectural University of Medicine
Principal Investigator	Matsubara Hiroki 京都府立医科大学, 医学(系)研究科(研究院), 客員講師 (00530362)
Co-Investigator(Kenkyū-buntansha)	松田修京都府立医科大学, 医学(系)研究科(研究院), 教授 (00271164) 岸田綱郎京都府立医科大学, 医学(系)研究科(研究院), 准教授 (00370205) 浮村理京都府立医科大学, 医学(系)研究科(研究院), 教授 (70275220)
Project Period (FY)	2019-04-01 – 2022-03-31
Keywords	膀胱平滑筋 / direct reprogramming / ダイレクトリプログラミング / 膀胱線維化 / 再生医療
Outline of Final Research Achievements	Bladder fibrosis is an irreversible condition that occurs when bladder contraction is chronically disturbed by nerve abnormalities. Atrophy or loss of smooth muscle cells and excessive deposition of extracellular matrix secreted by fibroblasts in the cystic stroma can reduce bladder contractility and bladder capacity, leading to increased urinary frequency and residual urine.No treatment has been established. We recently found that transfection of the MYOCD gene can convert human fibroblasts into smooth muscle cells by direct reprogramming. In this study, we performed fundamental research to apply this technology to establish a new regenerative medicine for bladder fibrosis.
Free Research Field	泌尿器外科学
Academic Significance and Societal Importance of the Research Achievements	これまでに我々の研究室では、遺伝子導入を用いて線維芽細胞を尿路上皮細胞に直接転換させる技術を開発し報告している。本研究では線維芽細胞から平滑筋細胞を直接転換させることにより、現在根本的治療のない膀胱線維化患者に対して、新規治療法を提供することが可能となり、また膀胱再生医療に大きく寄与できると考えられる。